Transcenta Holding Limited, a clinical-stage biopharmaceutical company based in Princeton, N.J., has announced a strategic collaboration with EirGenix Inc., a biopharmaceutical development firm located in Hangzhou, China. The agreement, made public on December 28, 2025, involves a non-exclusive licensing arrangement that allows EirGenix to utilize Transcenta’s proprietary Highly Intensified Continuous Bioprocessing (HiCB) platform.
Under the terms of this collaboration, EirGenix will have access to advanced process technologies, including highly productive continuous perfusion and integrated hybrid continuous purification processes. Additionally, Transcenta will provide comprehensive process documentation and regulatory support packages to facilitate the technology’s implementation.
This partnership is expected to benefit both companies significantly. Transcenta is set to receive substantial upfront and milestone payments, along with future royalty payments linked to the commercial use of the licensed technologies. Both organizations anticipate that this collaboration will generate long-term value in the biopharmaceutical market.
The HiCB platform represents a cutting-edge approach to biomanufacturing, aiming to enhance the efficiency and productivity of antibody-based therapeutics. By leveraging this technology, EirGenix aims to strengthen its development and manufacturing capabilities, potentially expanding its portfolio of biopharmaceutical products.
Transcenta’s CEO, Dr. Jianming Yu, expressed optimism about the collaboration, noting that it aligns with the company’s mission to innovate in the field of biopharmaceuticals. “We believe that this partnership will not only enhance our technological reach but also contribute to the advancement of therapies that can significantly improve patient outcomes,” he stated.
EirGenix’s CEO, Dr. Tzong-Shinn Lee, echoed this sentiment, highlighting the importance of strategic alliances in the rapidly evolving biopharmaceutical landscape. “This collaboration with Transcenta is a pivotal step for EirGenix as we work towards expanding our therapeutic offerings and improving efficiencies in our manufacturing processes,” he remarked.
Overall, this agreement marks a significant milestone for both Transcenta and EirGenix, as they join forces to leverage innovative technologies in the biopharmaceutical sector. With the global demand for effective therapies on the rise, such collaborations are likely to play a crucial role in shaping the future of drug development and manufacturing.
